Compare MASI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASI | NUVL |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.1B |
| IPO Year | 2000 | 2021 |
| Metric | MASI | NUVL |
|---|---|---|
| Price | $175.36 | $100.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $184.25 | $135.33 |
| AVG Volume (30 Days) | ★ 2.0M | 444.7K |
| Earning Date | 03-30-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,239,153,000.00 | N/A |
| Revenue This Year | $8.59 | N/A |
| Revenue Next Year | $7.60 | $714.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.34 | N/A |
| 52 Week Low | $125.94 | $55.54 |
| 52 Week High | $186.27 | $113.02 |
| Indicator | MASI | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 75.42 | 43.80 |
| Support Level | $136.90 | $98.65 |
| Resistance Level | N/A | $106.97 |
| Average True Range (ATR) | 1.57 | 4.49 |
| MACD | 1.54 | -0.18 |
| Stochastic Oscillator | 98.84 | 28.74 |
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.